Feds Put the Brakes On NexMed Cream

Gaudio, Thomas
July 2008
njbiz;7/28/2008, Vol. 21 Issue 31, p2
The article reports on the non-approval of the NexMed Cream by the U.S. Food and Drug Administration (FDA) because it could cause cancer at high doses in some mice. Vivian Liu, chief executive officer of NexMed, said that the genetically engineered mice they used is no longer an accepted animal model in drug research, which caused the abnormality. Liu added that they plan to generate data from more reliable animal model to alleviate the concern of the FDA. NexMed plans to market the cream to those who cannot tolerate the side effects of Viagra.


Related Articles

  • Sildenafil in the treatment of erectile dysfunction. Rose, Verna L. // American Family Physician;7/1/1998, Vol. 58 Issue 1, p268 

    Reports on the approval of the oral therapy sildenafil drug viagra, by the United States (US) Food and Drug Administration. Effectiveness of the drug; Side effects associated with the drug; Statement issued by the American Foundation for Urologic Disease.

  • FDA Challenges Implied Outcomes Claims for Several ADHD Products: An Analysis.  // Venulex Legal Summaries;2008 Q4, Special section p1 

    This article reports on the letters issued by the U.S. Food and Drug Administrations's (FDA) Division of Drug Marketing, Advertising and Communications challenging implied outcomes claims for several attention deficit hyperactivity disorder (ADHD) products. It advises pharmaceutical marketers to...

  • FDA issues new warnings for sildenafil.  // Urology Times;Jan99, Vol. 27 Issue 1, p3 

    Focuses on United States Food & Drug Administration's issuance of explicit warnings about the oral agent for erectile dysfunction called sildenafil citrate.

  • Dying for Lifesaving Drugs. Howley, Kerry // Reason;Aug/Sep2007, Vol. 39 Issue 4, p24 

    The article debates on the regulatory structure of the U.S. Food and Drug Administration (FDA) in approving lifesaving experimental drugs, that have passed phase 1 to 3 tests of the FDA testing. One of the drugs which has proven to save the life of a glioblastula multiforma (GBM) patient is...

  • ED drugs in the pipeline.  // Contemporary Urology;Nov2001, Vol. 13 Issue 11, p54 

    The article provides an update on drug approval in the U.S. as of November 2001. A new drug application for vardenafil was recently submitted to the U.S. Food & Drug Administration (FDA) for approval. Phase III data demonstrated that 20 milligram of tadalafil improved erections in majority of...

  • Viagra Turns 10. Neuman, Clayton // Fast Company;Mar2008, Issue 123, p40 

    The article looks at the erectile dysfunction prescription Viagra. Viagra, or the synthetic compound sildenafil citrate, was approved by the U.S. Food and Drug Administration in March 1998. It was developed by the pharmaceutical company Pfizer and is spoken for by U.S. celebrities like Bob Dole...

  • Hearing Loss and Drugs for Erectile Dysfunction.  // ASHA Leader;11/27/2007, Vol. 12 Issue 16, p5 

    The article discusses an investigation by the U.S. Food and Drug Administration (FDA) into the belief that the use of certain drugs, including Viagra, Levitra, Cialis, and Revatio, may lead to some hearing loss. The FDA has updated the labeling and adverse reactions that is provided with these...

  • Experts Urge Major Overhaul at FDA. Wechsler, Jill // Applied Clinical Trials;Nov2006, Vol. 15 Issue 11, p22 

    The article reports on the proposal for better prescription drug testing regulations by the Institute of Medicine (IOM) to the Food and Drug Administration (FDA) in the U.S. Due to the high-profile drug withdrawals and safety alerts, the public has raised doubts on the ability of FDA and the...

  • The AIDS Consumer Movement and the FDA: A Potential Paradigm Shift in Health Care Policy. Gould, Stephen J. // Journal of Public Policy & Marketing;1989, Vol. 8 Issue 1, p40 

    AIDS is having a dramatic effect on our society. As a result, a consumer movement has been formed which is seeking to change the way drugs are tested and used. In response, the FDA has slowly begun to make some changes in its drug policies. This paper documents the policy battle that is underway...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics